Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

AIDS

Volumn 22, Issue 14, 2008, Pages 1877-1880

  Van Baelen, Kurt ^a   Van Eygen, Veerle ^a   Rondelez, Evelien ^a   Stuyver, Lieven J ^a  

^a Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DNA BINDING; DRUG SENSITIVITY; ENZYME POLYMORPHISM; GENE MUTATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; VIRUS ISOLATION; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; PYRROLIDINONES; QUINOLONES;

EID: 66349126931     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830f9703     Document Type: Article

References (25)

1. Cannon PM, Byles ED, Kingsman SM, Kingsman AJ. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. I Virol 1996; 70:651-657.
2. LaFemina RL, Graham PL, LeGrow K, Hastings JC, Wolfe A, Young SD, et al. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob Agents Chemother 1995; 39:320-324.
3. Bushman FD, Engelman A, Palmer I, Wingfield P, Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci U S A1 993; 90:3428-3432.
4. Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992; 66:6361-6369.
5. Engelman A, Hickman AB, Craigie R. The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol 1994; 68:5911 -5917.
6. Vercammen J, Maertens G, Gerard M, De Clercq E, Debyser Z, Engelborghs Y. DNA-induced polymerization of HIV-1 integrase analyzed with fluorescence fluctuation spectroscopy. I Biol Chem 2002; 277:38045-38052.
7. Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase 2 study in patients with triple-class resistant HIV-1 infection. In: 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications; 2007; Barbados, West Indies.
8. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol2008; 82:764-774.
9. Cooper D, Gatell J, Rockstoh J. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California.
10. MaletI, DelelisO, ValantinMA, MontesB, SoulieC, WirdenM, et al. Biochemical characterization of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518). In: 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications; 2007; Barbados, West Indies.
11. Steigbigel R, Kumar P, Eron J. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California.
12. McColl DJ, Fransen S, Gupta S. Resistance and cross-resistance to first-generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). In: 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications; 2007; Barbados, West Indies.
13. Van Baelen K, Rondelez E, Van Eygen V, Van den Zegel P, Clynhens M, Vandenbroucke I, Stuyver LJ. Development of a genotypic and phenotypic recombinant virus assay to determine resistance against HIV-1 integrase inhibitors. In: European Society for Clinical Virology; 2008; Lapland, Finland.
14. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Fabeni L, Rondelez E, et al. Novel HIV-1 integrase mutations, found as minority quasispecies in patients naive to integrase inhibitors, are associated with decreased susceptibility to integrase inhibitors in vitro. In: 1 5th Conferenceon Retroviruses and Opportunistic Infections; 2008; Boston, Massachusetts.
15. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 11:S28.
16. Ceccherini-Silberstein F, Malet I, Fabeni L, Svicher V, Gori C, Dimonte S, et al. Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse tran-scriptase mutations in HAART-treated patients. Antivir Ther 2007; 12:S6.
17. Hackett J, Harris B, Holzmayer V, Yamaguchi J, Luk KC, Brennan C, et al. Naturally occuring polymorphisms in HIV-1 group M, N, and O integrase: implications for integrase inhibitors. In: 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, Massachusetts, USA.
18. Low A, Mohri H, MarkowitzM. Frequency of naturally occuring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA.
19. Myers RE, Pillay D. HIV-1 integrase sequence variation and covariation. Antivir Ther 2007; 12:S5.
20. Passaes C, Guimarães M, Lorete R, Fernandez J, Morgado M. Genetic diversity of integrase in HIV-1 subtypes B, F, and C, prevalent in Brazil: Study in drug-naive and multidrug-resistant individuals reveals impact for drug resistance. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA.
21. Suzuki H, Fujino M, Matsuda M, Yen H, Iwantani Y, Sugiura W. Effects of protease and reverse transcriptase inhibitor-resistance mutations on integrase polymorphism in multidrug resistance cases. Antivir Ther 2007; 12:S4.
22. Yerly S, Hirschel B, Gaille C, Kaiser L, Perrin L. Natural polymorphism if HIV-1 subtypes B and non-B integase gene. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA.
23. Zioni R, RheeS, LiuT, ShaferR. Natural variation of HIV-1 group M integrase: implications for integrase inhibitor therapy. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA.
24. Van Eygen V, Van Marck H, Smits V, Clynhens M, Rondelez E, Van Baelen K, Stuyver LJ. Identification of residues in HIV-1 integrase, RNAseH and the RT connection domain associated with the presence ofthymidine analogue-associated resistance. In: 6th European HIV Resistance Workshop; 2008; Budapest, Hungary.
25. Rondelez E, Van Baelen K, Ceccherini-Silberstein F, Van Eygen V, Van den Zegel P, Winters B, et al. Preliminary Biological Cutoffs for GS-9137 and MK-0518 integrase inhibitors derived from clonal phenotypic analysis. In: 6th European HIV Resistance Workshop; 2008; Budapest, Hungary.